GeoWealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

GeoWealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-621	Closed	-$68K	–	486
2023 Q1	$68K	Buy	+621	New	+$68.6K	0.01%	274
2022 Q3	–	Sell	-301	Closed	-$25K	–	383
2022 Q2	$25K	Buy	301 +33	+12%	+$3.13K	﹤0.01%	290
2022 Q1	$28K	Buy	268 +6	+2%	+$585	﹤0.01%	351
2021 Q4	$28K	Buy	262 +3	+1%	+$327	﹤0.01%	342
2021 Q3	$28K	Sell	259 -548	-68%	-$56.9K	﹤0.01%	346
2021 Q2	$75K	Buy	+807	New	+$74.3K	0.01%	223

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GeoWealth Management's HZNP Position: Q2 2023 in Review

GeoWealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 621 shares — an estimated $68K sold.

GeoWealth Management first reported a position in HZNP in Q2 2021 and held it in 6 quarters. The position peaked at $75K in Q2 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

GeoWealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
GeoWealth Management sold 621 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $68K.
GeoWealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 6 quarters.
GeoWealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $75K in Q2 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on GeoWealth Management's 13F filing for Q2 2023, filed 10 Aug 2023.